Cytokinetics (CYTK) Stock Forecast & Price Target

Cytokinetics is compelling fundamentally because MYQORZO is already showing strong early commercial traction, with 2Q26 product sales of about $25 million, more than 2,500 REMS-certified HCPs, and over 80% of patients on paid therapy, suggesting rapid adoption and improving payer access. Its growth case is further strengthened by broadening regulatory momentum, including approval in the U.S., China, the EU, the UK, and Canada, plus a PDUFA date of November 14, 2026 for MAPLE-HCM label expansion and an anticipated 4Q26 sNDA submission for nHCM. Clinical data also support a durable pipeline value, as ACACIA-HCM met both dual primary endpoints in nHCM with statistically significant gains in KCCQ-CSS and pVO2, while favorable secondary and echo findings reinforce aficamten’s potential across the HCM continuum.

Cytokinetics is burdened by meaningful clinical and regulatory uncertainty, as aficamten showed LVEF <50% in 10.5% of treated patients versus 0.8% on placebo, plus serious heart failure events and a −4.4% LVEF gap at week 36. Its lead program is still in Phase 3, so it has no profitable products and remains dependent on alliances and research revenues to fund operations. Even with manageable monitoring assumptions, the company faces the risk that FDA or ex-U.S. agencies demand more studies, while competitors could launch safer or cheaper alternatives and erode any future market share.